Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utilization by high-cost, high-need Medicaid patients receiving social worker care coordination.

The American journal of managed care·2026
Same author

Dimensions of Burnout and Predictors of Physician Turnover in Clinical Practice.

Journal of general internal medicine·2026
Same author

Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Neoadjuvant Chemotherapy, Case Volume, and Mortality in Advanced Ovarian Cancer.

JAMA network open·2025
Same author

Association of Socioeconomic Disadvantage With Postoperative Length of Stay.

The Journal of surgical research·2025
Same author

Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension: The NOTIFY-LVH Randomized Clinical Trial.

JAMA cardiology·2025
Same journal

Obstetric Care for Patients With Cognitive Disabilities.

Clinical obstetrics and gynecology·2026
Same journal

Dissecting the Americans With Disabilities Act (ADA) Requirements when Approaching Obstetric Patients With Disabilities: How to Ensure Your Spaces are Accessible for All.

Clinical obstetrics and gynecology·2026
Same journal

Clinician Comfort and Barriers to the Obstetric and Gynecologic Care of Patients With Disabilities.

Clinical obstetrics and gynecology·2026
Same journal

Obstetric Care for Patients With Visual Impairments: Preconception Counseling Through Postpartum Care.

Clinical obstetrics and gynecology·2026
Same journal

Menstrual Management and Contraception for Patients With Disabilities.

Clinical obstetrics and gynecology·2026
Same journal

Favoring Elective Hospitalization in Pregnancies With Vasa Previa.

Clinical obstetrics and gynecology·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Recurrent endometrial cancer.

Marcela G Del Carmen1, David M Boruta, John O Schorge

  • 1Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology Service, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Clinical Obstetrics and Gynecology
|April 22, 2011
PubMed
Summary
This summary is machine-generated.

Endometrial cancer treatment varies by stage and grade. Recurrent endometrial cancer requires individualized approaches, considering surgery, radiation, hormonal therapy, chemotherapy, and biological agents.

More Related Videos

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
05:16

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage

Published on: August 4, 2021

Related Experiment Videos

Last Updated: Jun 2, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
05:16

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage

Published on: August 4, 2021

Area of Science:

  • Gynecologic Oncology
  • Malignancy Research

Background:

  • Endometrial cancer is the most common gynecologic malignancy in the U.S.
  • Early-stage, low-grade endometrioid tumors are highly curable with surgery.
  • Advanced or higher-grade disease carries a higher risk of recurrence.

Purpose of the Study:

  • To review treatment options for recurrent endometrial cancer.
  • To highlight the heterogeneity of recurrent endometrial cancer patients.
  • To emphasize the need for individualized treatment strategies.

Main Methods:

  • Review of current treatment modalities.
  • Analysis of recurrence risk factors.
  • Discussion of therapeutic options for diverse patient groups.

Main Results:

  • Uterine papillary serous and clear cell carcinomas, though infrequent, cause nearly half of all recurrences.
  • Recurrent endometrial cancer patients form a heterogeneous group.
  • Multimodality therapy is often required for advanced disease.

Conclusions:

  • Individualized treatment is essential for managing recurrent endometrial cancer.
  • Treatment options include surgery, radiation, hormonal therapy, chemotherapy, and biological agents.
  • Understanding tumor subtypes and patient heterogeneity is key for effective management.